Abbonarsi

Integrative assessment of high-sensitivity C-reactive protein and lipid levels in predicting 20-year atherosclerotic cardiovascular disease risk, in a Mediterranean population: The ATTICA study (2002-2022) - 20/08/26

Doi : 10.1016/j.ahj.2026.107540 
Sofia-Panagiota Giannakopoulou, MSc, PhDc a, Christina Chrysohoou, MD, PhD b, Smaragdi Antonopoulou, PhD a, Fotios Barkas, MD, PhD c, Evangelos Liberopoulos, MD, PhD d, Petros P. Sfikakis, MD, PhD d, Christos Pitsavos, MD, PhD b, Costas Tsioufis, MD, PhD b, Demosthenes Panagiotakos, PhD a,
a Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece 
b First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece 
c Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece 
d First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece 

Reprint requests: Demosthenes Panagiotakos, PhD, Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, 70 El. Venizelou Avenue, Kallithea, Athens 17676, Greece. Department of Nutrition and Dietetics, School of Health Sciences and Education Harokopio University 70 El. Venizelou Avenue, Kallithea Athens 17676 Greece

Highlights

Hs-CRP provides incremental predictive value, even beyond advanced lipid metrics.
Elevated apoB increased MACE-3p risk, irrespective of hs-CRP.
Hs-CRP was an independent MACE-3p risk factor, adjusting for LDL-C or non-HDL-C.
Elevated LDL-C/non-HDL-C increased MACE-3p risk only when hs-CRP was also elevated.
Even in low-risk settings, hs-CRP remains a potent residual risk factor.

Il testo completo di questo articolo è disponibile in PDF.

ABSTRACT

Background

While inflammation is recognized as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), with high-sensitivity C-reactive protein (hs-CRP) serving as a prognostic indicator, the degree to which elevated hs-CRP combined with different atherogenic lipid measures increases long-term ASCVD risk remains unclear in primary prevention cohorts of Mediterranean origin, who exhibit a comparatively favorable inflammatory profile due to lifestyle and dietary habits. Thus, this study aimed to examine the association between combined hs-CRP and various atherogenic lipid measures and long-term 3-point MACE risk in apparently healthy adults from the general population.

Methods

A cohort of 3,042 ASCVD-free adults residing in greater Athens, Greece, was recruited in 2002. A 20-year follow-up was conducted in 2022, comprising n = 2,169 participants, of which n = 1,988 had complete data for cardiovascular disease incidence. Participants were grouped based on discordance between biomarkers, defined by established guideline-recommended thresholds.

Results

Hs-CRP was an independent predictor of incident 3-point MACE after adjusting for low-density lipoprotein cholesterol (LDL-C) or nonhigh-density lipoprotein cholesterol (non-HDL-C), but not apolipoprotein B (apoB) or lipoprotein(a) (Lp(a)). High levels of apoB (≥100 mg/dL) were associated with an increased 3-point MACE risk regardless of hs-CRP levels. However, elevated LDL-C (≥100 mg/dL) and non-HDL-C (≥131 mg/dL) showed significant associations only in the presence of hs-CRP ≥ 2 mg/L.

Conclusions

Hs-CRP provides independent, incremental predictive value, even beyond advanced lipid metrics, and is a potent residual risk factor in contexts traditionally considered low-risk.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Image, graphical abstract

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2026  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 301

Articolo 107540- novembre 2026 Ritorno al numero
Articolo precedente Articolo precedente
  • Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: A descriptive compatibility analysis
  • Thomas C. Scheier, Hertzel C. Gerstein, Arend Mosterd, Qilong Yi, John Eikelboom
| Articolo seguente Articolo seguente
  • Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial
  • Guangyu Tong, Yukang Zeng, Stephen J. Greene, Kevin J. Anstrom, Jeffrey Testani, Robert J. Mentz, Fan Li, Eric J. Velazquez

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.